Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 1;58(3):401-403.
doi: 10.1093/mmy/myz056.

Viability of pathogenic dermatophytes during a 4-week treatment with 1% topical luliconazole for tinea pedis

Tomoyuki Iwanaga  1 , Tsuyoshi Ushigami  1 , Kazushi Anzawa  1 , Takashi Mochizuki  1
Affiliations

Viability of pathogenic dermatophytes during a 4-week treatment with 1% topical luliconazole for tinea pedis

Tomoyuki Iwanaga et al. Med Mycol. .

Abstract

The viability of pathogenic fungi in the scale was investigated during topical administration of 1% luliconazole (LLCZ). Thirteen tinea pedis patients found to be positive on KOH examination were assessed by mycological examinations and quantitative real-time polymerase chain reaction (PCR) targeted internal transcribed spacer (ITS) in ribosomal RNA gene at the initial visit and after 2 and 4 weeks of treatment. Assays showed that the average copy number of ITS DNA had significantly decreased to 22.9% at 2 weeks and 4.8% at 4 weeks compared with the initial visit. LLCZ topical treatment could defeat almost pathogenic dermatophytes in the scales within 4 weeks.

Keywords: dermatophyte; luliconazole; quantitative real-time PCR; tinea pedis; viability.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
ITS DNA amount after 1% topical LLCZ treatment. Patients were treated with 1% topical LLCZ for 4 weeks. The amount of ITS DNA in scales was measured at 0, 2, and 4 weeks by qPCR, and calculated relative to the initial visit (100%). Each bar represents the mean ± standard deviation of duplicate samples with results analyzed statistically by one-way ANOVA with Tukey–Kramer post hoc analysis. **P < .01. n = 12 at initial visit and 2 weeks, and n = 10 at 4 weeks.
See this image and copyright information in PMC

References

    1. Niwano Y, Kuzuhara N, Kodama H, Yoshida M, Miyazaki T, Yamaguchi H. In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent. Antimicrob Agents Chemother. 1998; 42: 967–970. - PMC - PubMed
    1. Niwano Y, Koga H, Kodama H, Kanai K, Miyazaki T, Yamaguchi H. Inhibition of sterol 14 alpha-demethylation of Candida albicans with NND-502, a novel optically active imidazole antimycotic agent. Med Mycol. 1999; 37: 351–355. - PubMed
    1. Uchida K, Nishiyama Y, Yamaguchi H. In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent. J Infect Chemother. 2004; 10: 216–219. - PubMed
    1. Koga H, Tsuji Y, Inoue K et al.. In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses. J Infect Chemother. 2006; 12: 163–165. - PubMed
    1. Koga H, Nanjoh Y, Makimura K, Tsuboi R. In vitro antifungal activities of luliconazole, a new topical imidazole. Med Mycol. 2009; 47: 640–647. - PubMed